期刊
JOURNAL OF INVESTIGATIVE DERMATOLOGY
卷 140, 期 5, 页码 1003-+出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jid.2019.09.018
关键词
-
类别
资金
- Eurostars Grant [E1 7783]
- Swiss National Science Foundation [310030-172978]
- Hochspezialisierte Medizin Schwerpunkt Immunologie (HSM-2-Immunologie)
- University of Zurich
- University Hospital Zurich
- Swiss National Science Foundation (SNF) [310030_172978] Funding Source: Swiss National Science Foundation (SNF)
Methotrexate (MTX) is an antiproliferative drug used for treating inflammatory diseases, including psoriasis. Nevertheless, its use in localized therapy is hindered because of poor transdermal penetration. We show that MTX coupled with gold nanoparticles (GNPs) demonstrates superior antiinflammatory efficacy than MTX alone in an imiquimod-induced mouse model, significantly reducing gd T cells, CD4thorn T cells, and neutrophils. Furthermore, it was well tolerated upon systemic and topical administration. In an AGR129 human xenograft mouse model, two-week topical treatment with MTX-GNPs inhibited skin hyperplasia significantly better than topical calcipotriol-betamethasone and led to profound tissue remodeling, involving the upregulation of extracellular matrix reorganization and the downregulation of cornification and keratinization processes. The number of resident T cells in the grafts, as well as interleukin-17 production, drastically decreased upon MTXGNP treatment. While both MTX and MTX-GNPs directly prevented the proliferation and induced apoptosis of T cells, the suppression of cytokine production was a shared mechanism of GNP and MTX-GNPs. In conclusion, MTX-GNPs influence immune and stromal components of the skin, leading to the potent inhibition of pathogenesis in preclinical psoriasis. MTX-GNPs surpass the efficacy of conventional MTX and standard of care, emerging as a non-steroidal, topical alternative for psoriasis treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据